Diffuse alveolar hemorrhage (DAH) is a rare but life-threatening complication of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with management largely extrapolated from broader AAV and ARDS literature. We conducted a review of studies published between 2000 and 2025 evaluating treatments and outcomes in AAV-associated DAH, synthesizing evidence across immunosuppressive, plasmapheresis, hemostatic, respiratory and hemodynamic, and infection prevention strategies. Glucocorticoids combined with rituximab or cyclophosphamide induce remission in most patients, although optimal steroid tapering and comparative efficacy in severe, ventilated DAH remain uncertain. Avacopan improves sustained remission and renal recovery in severe AAV and appears to be a feasible steroid-sparing adjunct in early DAH series. Large randomized trials demonstrate no survival benefit of plasma exchange. Local hemostatic therapies may provide rapid bleeding control, but evidence is limited. Respiratory outcomes are driven by hypoxemia severity and need for invasive ventilation or extracorporeal support. Lastly, infection prevention measures are strongly supported.

The lunula, the half-moon shaped visible portion of the distal matrix most apparent in the thumbs, is typically white in appearance and contributes to the shape of the nail plate. Abnormal coloration of the lunula may signify an underlying disease. Red lunula, a rare but clinically salient finding, can implicate systemic disease or a local disorder isolated to the fingernail. First described in 1954, numerous other cases have since been delineated and an association with cardiovascular, hepatic, hematologic, dermatologic, and rheumatologic disorders has been apparent. Though the precise etiology remains unclear, red lunulae may reflect both systemic disease activity or local pathology such as subungual tumors. Given the rarity of the occurrence, its potential diagnostic relevance is often overlooked. When identifying red lunulae, clinicians should consider connections to underlying systemic or dermatologic disease. This subtle clinical sign may facilitate early detection and identification of salient systemic disease.

The increasing prevalence of cardiovascular diseases (CVD) and type 2 diabetes, particularly among younger populations, highlights the urgent need for early, cost-effective risk assessment tools. The Triglyceride-Glucose (TyG) index, derived from routine triglyceride and glucose levels, has emerged as a reliable predictor of insulin resistance and is gaining recognition for its role in forecasting cardiovascular risk, including Major Adverse Cardiac and Cerebrovascular Events (MACCE). Unlike more complex and costly insulin resistance tests, the TyG index offers a simpler approach to early detection, particularly in individuals without obvious clinical signs of metabolic disease. This narrative review synthesizes evidence on the association between the TyG index and various cardiovascular outcomes, focusing on early-onset conditions such as atherosclerotic cardiovascular disease (ASCVD), myocardial infarction (MI), coronary artery disease (CAD), stroke, heart failure, and all-cause mortality. Notably, the TyG index has shown predictive value across diverse patient populations, including those free from diabetes or dyslipidemia.

Headache is an underrecognized manifestation of hypoglycemia in individuals with diabetes. Although hypoglycemia is well known to produce autonomic and neuroglycopenic symptoms, headache is frequently overlooked as a potential indicator of low glucose, which may lead to unnecessary diagnostic evaluation and missed opportunities to prevent recurrent episodes. A landmark pre-CGM study reported hypoglycemia-related headache in 43% of insulin-treated individuals experiencing hypoglycemia, although contemporary prevalence estimates remain uncertain. Recognition of the temporal relationship between headache episodes and glucose fluctuations is essential for accurate diagnosis. Continuous glucose monitoring can help identify symptomatic and asymptomatic hypoglycemia associated with headache and support prevention through real-time alerts and pattern recognition. This review summarizes the pathophysiology, clinical presentation, diagnostic evaluation, and management of hypoglycemia-related headache and provides a practical clinical approach, including a diagnostic algorithm, to assist clinicians in evaluating headache complaints in patients with diabetes.

T cells and their subsets play dual roles in the pathogenesis, progression, and repair of kidney injury, acting as both drivers of inflammation and fibrosis and regulators of immune homeostasis and tissue repair. Although previous research has predominantly focused on the role of T cells in classic immune-mediated kidney diseases such as lupus nephritis and glomerulonephritis, with relatively less emphasis on their involvement in broader kidney injury contexts, emerging evidence reveals a more extensive and spatiotemporally specific regulatory network of T-cell subsets in acute kidney injury (AKI), chronic kidney disease (CKD), and transplant kidney injury. Within the pathological processes of kidney injury, distinct T-cell subsets contribute to disease progression through specific mechanisms. For instance, Th17 cells exacerbate acute and chronic inflammation and fibrosis via IL-17-dependent pathways, yet may contribute to repair in later injury phases. This review primarily outlines the impact of different T-cell subsets on kidney injury and explores strategies for their therapeutic targeting.

Cardiac allograft vasculopathy (CAV) is a major cause of long-term complications in heart transplant (HTx) recipients, with dyslipidemia playing a key role in its development. While statins are the standard therapy, their effectiveness can be limited by side effects, insufficient lipid-lowering response, or drug interactions. This scoping review examines the emerging role of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) as an alternative strategy, emphasizing their positive effects on lipid profiles, especially low-density lipoprotein cholesterol (LDL-c), in slowing CAV progression. Recent preclinical studies using a heterotopic murine heart transplant model have identified a novel finding: the PCSK9i "alirocumab" may protect against transplant rejection through mechanisms independent of lipid-lowering, possibly by modulating hepatic immune responses. These findings reveal a significant evidence frontier and highlight the need for clinical research to further explore the immunomodulatory properties of PCSK9i in the context of heart transplantation.